Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 2, 2007 - Issue 9
Submit an article Journal homepage
115
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Novel 8-heterocyclyl xanthine derivatives in drug development – an update

Pier G Baraldi Università di Ferrara, Dipartimento di Scienze Farmaceutiche, 44100 Ferrara, Italy +39 0532 455921; +39 0532 455953; [email protected]
,
Francesca Fruttarolo Università di Ferrara, Dipartimento di Scienze Farmaceutiche, 44100 Ferrara, Italy +39 0532 455921; +39 0532 455953; [email protected]
, PhD,
Mojgan A Tabrizi Università di Ferrara, Dipartimento di Scienze Farmaceutiche, 44100 Ferrara, Italy +39 0532 455921; +39 0532 455953; [email protected]
, PhD,
Romeo Romagnoli Università di Ferrara, Dipartimento di Scienze Farmaceutiche, 44100 Ferrara, Italy +39 0532 455921; +39 0532 455953; [email protected]
, PhD &
Delia Preti Università di Ferrara, Dipartimento di Scienze Farmaceutiche, 44100 Ferrara, Italy +39 0532 455921; +39 0532 455953; [email protected]
, PhD
Pages 1161-1183 | Published online: 29 Aug 2007

Bibliography

  • BRUNS RF: Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. (1981) 30(4):325-333.
  • DALY JW: Adenosine receptors: targets for future drugs. J. Med. Chem. (1982) 25(3):197-207.
  • LAINEZ MJ, GALVAN J, HERAS J, VILA C: Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol. (2007) 14(3):269-275.
  • ABO-SALEM OM, HAYALLAH AM, BILKEI-GORZO A, FILIPEK B, ZIMMER A, MULLER CE: Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. (2004) 308(1):358-366.
  • BARNES PJ: Drugs for asthma. Br. J. Pharmacol. (2006) 147(1):S297-S303.
  • BOSWELL-SMITH V, CAZZOLA M, PAGE CP: Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. (2006) 117(6):1237-1243.
  • BOSWELL-SMITH V, SPINA D, PAGE CP: Phosphodiesterase inhibitors. Br. J. Pharmacol. (2006) 147(1):S252-S257.
  • BARNES PJ: Reduced histone deacetylase in COPD: clinical implications. Chest (2006) 129(1):151-155.
  • JACOBSON KA, GAO ZG: Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov. (2006) 5(3):247-264.
  • EL-SABBAGH OI, EL-SADEK ME, EL-KALYOUBI S, ISMAIL I: Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivatives. Arch. Pharm. Chem. Life Sci. (2007) 340(1):26-31.
  • VLOK N, MALAN SF, CASTAGNOLI NJR, BERGH JJ, PETZER JP: Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg. Med. Chem. (2006) 14(10):3512-3521.
  • SUZUKI H, SAWANISHI H, YAMAMOTO K, YOKOGAWA K, MIYAMOTO K: Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-phenyl[i]condensed-purines. Chem. Pharm. Bull. (2001) 49(2):188-191.
  • WANG Y, CHACKALAMANNIL S, HU Z et al.: Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(21):3149-3152.
  • COTTAM HB, SHIH H, TEHRANI LR, WASSON DB, CARSON DA: Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of TNF. J. Med. Chem. (1996) 39(1):2-9.
  • KLINGER M, FREISSMUTH M, NANOFF C: Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal. (2002) 14(2):99-108.
  • DALY JW, BUTTS-LAMB P, PADGETT W: Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. (1983) 3(1):69-80.
  • STEHLE JH, RIVKEES SA, LEE JJ, WEAVER DR, DEEDS JD, REPPERT SM: Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol. Endocrinol. (1992) 6(3):384-393.
  • FEOKTISTOV I, BIAGGIONI I: Adenosine A2B receptors. Pharmacol. Rev. (1997) 49(4):381-402.
  • FREDHOLM BB, IJZERMAN AP, JACOBSON KA, KLOTZ KN, LINDEN J: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53(4):527-552.
  • Volpini R, COSTANZI S, VITTORI S, CRISTALLI G, KLOTZ KN: Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem. (2003) 3(4):427-443.
  • Cacciari B, PASTORIN G, BOLCATO C, SPALLUTO G, BACILIERI M, MORO S: A2B adenosine receptor antagonists: recent developments. Mini Rev. Med. Chem. (2005) 5(12):1053-1060.
  • RORKE S, HOLGATE ST: Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Med. (2002) 1(2):99-105.
  • RYZHOV S, GOLDSTEIN AE, MATAFONOV A, ZENG D, BIAGGIONI I, FEOKTISTOV I: Adenosine-activated mast cells induce IgE synthesis by B Lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J. Immunol. (2004) 172(12):7726-7733.
  • SANDS WA, PALMER TM: Adenosine receptors and the control of endothelial cell function in inflammatory desease. Immunol. Lett. (2005) 101(1):1-11.
  • LIVINGSTON M, HEANEY LG, ENNIS M: Adenosine, inflammation and asthma-a review. Inflamm. Res. (2004) 53(5):171-178.
  • BEUKERS MW, MEURS I, IJZERMAN AP: Structure-affinity relationships of adenosine A2B receptor ligands. Med. Res. Rev. (2006) 26(5):667-698.
  • FEOKTISTOV I, WELLS JN, BIAGGIONI I: Adenosine A2B receptors as therapeutic targets. Drug Dev. Res. (1998) 45(3):198-206.
  • KIM SA, MARSHALL MA, MELMAN N et al.: Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J. Med. Chem. (2002) 45(11):2131-2138.
  • KIM YC, JI XD, MELMAN N, LINDEN J, JACOBSON KA: Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptor. J. Med. Chem. (2000) 43(6):1165-1172.
  • BARALDI PG, TABRIZI MA, PRETI D et al.: Design, synthesis and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J. Med. Chem. (2004) 47(6):1434-1447.
  • ZABLOCKI J, KALLA R, PERRY T et al.: The discovery of a selective, high affinity A2B receptor antagonist for the potential treatment of asthma. Bioorg. Med. Chem. Lett. (2005) 15(3):609-612.
  • ELZEIN E, KALLA RV, LI X et al.: Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16(2):302-306.
  • KALLA RV, ELZEIN E, PERRY T et al.: Novel 1,3-Disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists. J. Med. Chem. (2006) 49(12):3682-3692.
  • CAROTTI A, CADAVID MI, CENTENO NB et al.: Design, synthesis and structure-activity relationships of 1-, 3-, 8- and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J. Med. Chem. (2006) 49(1):282-299.
  • ESTEVE C, NUEDA A, DIAZ JL et al.: New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16(14):3642-3645.
  • YAN L, BERTARELLI DCG, HAYALLAH AM et al.: A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. J. Med. Chem. (2006) 49(14):4384-4391.
  • FEOKTISTOV I, GARLAND ME, GOLDSTEIN AE et al.: Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX). Biochem. Pharmacol. (2001) 62(9):1163-1173.
  • BAZIARD-MOUYSSET G, RACHED A, YOUNES S et al.: Synthesis and in vitro bronchospasmolytic activity of 8-aryl, heteroaryl or arylalkyl theophyllines. Eur. J. Med. Chem. (1995) 30(3):253-260.
  • REGNIER GL, GUILLONNEAU CG, DUHAULT JL, TISSERAND FP, SAINT-ROMAS G, HOLSTORP SM: New xanthine derivatives with potent and long lasting anti-bronchoconstrictive activity. Eur. J. Med. Chem. (1987) 22(3):243-250.
  • PROFIRE L, BUMBU GG, COSTULEANU M, DANILA G, VASILE C: Thermal and pharmacological characterization of some new bis-xanthine derivatives. Termochimica Acta (2002) 381(1):19-29.
  • BERK B, AKGUN H, EROL K, SIRMAGUL B, GAO Z-G, JACOBSON KA: New 8-substituted xanthine derivatives as bronchodilators. Farmaco (2005) 60(11-12):974-980.
  • MÜLLER CE: A1 adenosine receptors and their ligands: overview and recent developments. Farmaco (2001) 56(1):77-80.
  • KIESMAN WF, ZHAO J, CONLON PR: Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J. Med. Chem. (2006) 49(24):7119-7131.
  • YUZLENKO O, KIEC'-KONONOWICZ K: Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr. Med. Chem. (2006) 13(30):3609-3625.
  • DHALLA A V, SHRYOCK JC, SHREENIWAS R, BELARDINELLI L: Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem. (2003) 3(4):369-385.
  • PFISTER JR, BELARDINELLI L, LEE G et al.: Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]-xanthine. J. Med. Chem. (1997) 40(12):1773-1778.
  • KIESMAN WF, ZHAO J, CONLON PR et al.: Norbornyllactone-substituted xanthines as adenosine A1 receptor antagonists. Bioorg. Med. Chem. (2006) 14(11):3654-3661.
  • STRAPPAGHETTI G, CORSANO S, BARBARO R, GIANNACCINI G, BETTI L: Structure–activity relationships in a series of 8-substituted xanthines as A1-adenosine receptor antagonists. Bioorg. Med. Chem. (2001) 9(3):575-583.
  • ILAS J, PECAR S, HOCKEMEYER J, EULER H, KIRFEL A, MULLER CE: Development of spin-labeled probes for adenosine receptors. J. Med. Chem. (2005) 48(6):2108-2114.
  • ENGEL M, HOFFMANN T, MANHART S et al.: Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. J. Mol. Biol. (2006) 355(4):768-783.
  • WEBER AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. (2004) 47(17):4135-4141.
  • KOLTERMAN OG, BUSE JB, FINEMAN MS et al.: Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. Clin. Endocrinol. Metab. (2003) 88(7):3082-3089.
  • AUGUSTYNS K, VAN DER VEKEN P, HAEMERS A: Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes. Expert Opin. Ther. Patents (2005) 15(10):1387-1407.
  • AUGUSTYNS K, VAN DER VEKEN P, SENTEN K, HAEMERS A: The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. (2005) 12(8):971-998.
  • KURUKULASURIYA R, ROHDE JJ, SZCZEPANKIEWICZ BG et al.: Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. (2006) 16(24):6226-6230.
  • LONGENECKER KL, STEWART KD, MADAR DJ et al.: Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors. Biochemistry (2006) 45(24):7474-7482.
  • SZCZEPANKIEWICZ BG, KURUKULASURIYA R: Aromatic heterocycle-based DPP-IV inhibitors: xanthines and related structural types. Curr. Top. Med. Chem. (2007) 7(6):569-578.
  • BRADLEY MN, TONTONOZ P: LXR: a nuclear receptor target for cardiovascular disease? Drug Discov. Today Ther. Strat. (2005) 2(2):97-103.
  • JAYE M: LXR agonists for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs (2003) 4(9):1053-1058.
  • BENNETT DJ, BROWN LD, COOKE AJ, EDWARDS AS: An update on non-steroidal liver X receptor agonists and their potential use in the treatment of atherosclerosis. Expert Opin. Ther. Patents (2006) 16(12):1673-1699.
  • CAO G, BALES KR, DEMATTOS RB, PAUL SM: Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. (2007) 4(2):179-184.
  • DELVECCHIO CJ, BILAN P, RADFORD K et al.: Liver X receptor stimulates cholesterol efflux and inhibits expression of pro-inflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. (2007) (In Press).
  • CHUU CP, KOKONTIS JM, HIIPAKKA RA, LIAO S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. (2007) (In Press).
  • CHUU CP, HIIPAKKA RA, KOKONTIS JM, FUKUCHI J, CHEN RY, LIAO S: Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. (2006) 66(13):6482-6486.
  • BARALDI PG, ROMAGNOLI R, PRETI D, FRUTTAROLO F, CARRION MD, TABRIZI MA: Ligands for A2B adenosine receptor subtype. Curr. Med. Chem. (2006) 13(28):3467-3482.

Patent

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.